




## The Human Brain Project (HBP) FET Flagship Call for Expressions of Interest (CEoI) on

## "CDP6 - Modelling allosteric drugs"

Call publication date:	10.07.2017
Proposal Submission Deadline:	30.09.2017
Call topic	Modelling allosteric drugs
Integration of call in HBP	SGA2 - starting 01.04.2018
Timeframe (set by HBP SGA2)	01.04.2018 - 31.03.2020
Total Budget of new Subproject (EU funding under HBP SGA2):	Total Call-Budget: <b>EUR 225.000</b> (including 25% indirect costs) One proposal for two partners will be selected. Co-funding and/or In-kind contributions not requested, but valued.
More information	drug-design@opencalls.humanbrainproject.eu
Proposal submission	Proposal submission for CDP6 Modelling Allosteric Drugs

- The Call for Expression of Interest (CEoI) addresses "Modeling allosteric drugs" as part of the HBP Co-Design Project 6 (CDP6). The topic is focused on novel molecular-simulation based research efforts to accelerate the discovery of new and more effective treatments, based on allosteric mechanisms, reducing the problem of side effects, whilst speeding up and drastically lowering the cost of drug discovery.
- In this CEoI one proposal for two partners will be selected. The winning proposal will become part of the envisioned overall HBP Work Plan for the second Specific Grant Agreement (SGA2; 1 April 2018 to 31 March 2020) as new Tasks and will be located in CDP6 in Subproject<sup>1</sup> 08.
- Under this CEoI, up to two potential new Partners are expected to group up to submit a
  proposal for a challenging project addressing high-level Use Cases for Modelling
  allosteric drugs. The suggested approach must have the potential to yield disruptive
  results while demonstrating a very high quality of participating partners.
- The proposal must be compatible with the requirements of the CEoI, as specified in the guide for applicants. The proposal should also describe precisely what will be delivered in each area relevant to the scope of the call. Contribution to the project activity reports will be required from the new Partners; for example, reporting on resources used in the period.
- Organisations, either already part of the HBP Consortium or not, are eligible for funding under this CEoI. Laboratories already receiving funding in SGA2 are not allowed to apply for the Call budget. They can only act as supporting Partners without asking for additional funding. A laboratory not receiving HBP funding but being part of a

https://www.humanbrainproject.eu/en/collaborate/open-calls/subprojects-ceols/





university or organisation that is already a Partner in the HBP is eligible to participate in the Call.

- Proposals can only be submitted by organisations established in the EU Member States or Horizon 2020 associated countries<sup>2</sup>.
- The parent organisations of the applicants that put forward the winning proposals, will become full Partners in the HBP Consortium, subject to the HBP Framework Partnership Agreement (FPA) and will be required to sign the HBP Consortium Agreement. The addition of new Partners to the Consortium is subject to the approval of the required FPA amendment by the HBP Stakeholder Board and the EC.
- Success in this Call should not be considered as a commitment by the HBP or the EC to continue funding the work that is the focus of this Call after the end of the SGA2 period. The continuation of this activity will be subject to the same review as all other HBP activities.
- It is expected that only those proposals that bridge several different *HBP disciplines*, will prove *visionary* enough (in the sense that they have the potential to *yield disruptive results* while demonstrating a *very high quality of participating partners*).
- Organisations of prospective project Partners submitting proposals for this call are expected to have a strong track record in developing computational methods used in modelling for drug discovery.
- In particular, the selected proposals should address the following points:
  - Explain the proposed research plan, its importance, novelty and potential breadth; describe its 24-months perspectives, and indicate how it could contribute to a longer term vision (in a time frame of 5 to 7 years).
  - Describe the contribution of your proposal to go beyond the state of the art, as well as its novelty and its Science &Technology prospects.
  - Describe the feasibility of what you propose by including a detailed and realistic research plan for the second phase of the HBP core project under H2020 (1 April 2018 to 31 March 2020).
  - Describe your concrete objectives and results that you would reach in the next two years.
  - Describe the way by which these objectives and results will be reached, i.e., the tasks, methods and experiments that you will use; the major milestones of your work etc.
  - Describe ethical implications of your work and compliance with applicable international, EU and national law.

Funding will be granted for a period of 24 months (1 April 2018 to 31 March 2020). The planned total budget of the call is EUR 250,000 (EU contribution including 25% indirect costs, H2020 rules), for one proposal with two partners.

Please note that under this CEoI, you may participate in more than one proposal. More information, including the Proposal Submission Template and Guide for Applicants, can be found on the website: <a href="Proposal submission for CDP6 Modelling Allosteric Drugs">Proposal submission for CDP6 Modelling Allosteric Drugs</a>

If you have further questions, please contact us at <a href="mailto:drug-design@opencalls.humanbrain">drug-design@opencalls.humanbrain</a> project.eu

<sup>&</sup>lt;sup>2</sup> The countries eligible to apply are all the EU Member States and the H2020 Associated Countries. For eligibility of other countries, see <a href="http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/international-cooperation\_en.htm">http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/international-cooperation\_en.htm</a>.